老年丙型肝炎病毒相关弥漫大B细胞淋巴瘤的生物学特征与结局:Fondazione Italiana Linfomi前瞻性「老年项目」结果
本研究为Fondazione Italiana Linfomi「老年项目」多中心前瞻性观察研究,比较65岁及以上弥漫大B细胞淋巴瘤患者中丙型肝炎病毒阳性(HCV+)与阴性(HCV-)病例的生物学和临床特征。1095例接受HCV血清学检测者中识别出89例HCV+(8.1%)。HCV+患者更年长、体能状态更差、结外受累频繁;经中心复核确诊为弥漫大B细胞淋巴瘤的病例中,HCV+与HCV-的3年总生存相似(63% vs 61%,p=0.926)。
要点
- 1095例接受HCV血清学检测的老年弥漫大B细胞淋巴瘤患者中,HCV+ 89例(8.1%)。
- HCV+患者较HCV-更年长、体能更差、结外受累更频繁。
- 经中心复核确诊者中,HCV+与HCV-的3年总生存相似(63% vs 61%,p=0.926)。
核心结论
- 在老年弥漫大B细胞淋巴瘤患者中,HCV+与HCV-的3年总生存相似(63% vs 61%,p=0.926)。
- 20例HCV+患者接受直接抗病毒药物(DAAs)治疗,耐受良好且全部获得持续病毒学应答,该亚组3年无进展生存为77%。
研究设计与样本
- Fondazione Italiana Linfomi开展的多中心前瞻性观察研究「老年项目」,纳入年龄≥65岁的弥漫大B细胞淋巴瘤患者,采用简化综合老年评估。
- 1095例接受HCV血清学检测的患者中识别出89例HCV+(8.1%),比较HCV+与HCV-病例的生物学和临床特征。
主要发现
- HCV+患者更年长、体能状态更差、结外受累频繁。
- Nanostring细胞起源测定显示,HCV+病例中活化B细胞型比例低于HCV-患者(18% vs 43%)。
- 86%的HCV+患者接受了利妥昔单抗-环磷酰胺、多柔比星、长春新碱(Oncovin)和泼尼松(R-CHOP)类免疫化疗,3-4级肝毒性发生率为3%。
- 经中心复核确诊为弥漫大B细胞淋巴瘤的病例中,HCV+与HCV-的3年总生存相似(63% vs 61%,p=0.926)。
- 20例HCV+患者接受DAAs治疗,耐受良好且全部获得持续病毒学应答,该亚组3年无进展生存为77%。
关键数值与推荐
- 1095例接受HCV血清学检测的患者中HCV+ 89例(8.1%)。
- HCV+病例活化B细胞型比例为18%,HCV-患者为43%。
- 86%的HCV+患者接受R-CHOP类免疫化疗,3-4级肝毒性发生率为3%。
- 经中心复核确诊为弥漫大B细胞淋巴瘤的病例中,HCV+与HCV-的3年总生存分别为63%与61%(p=0.926)。
- 20例接受DAAs治疗的HCV+患者全部获得持续病毒学应答,该亚组3年无进展生存为77%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Up to 10%-15% of diffuse large B-cell lymphoma (DLBCL) are related to hepatitis C virus (HCV) infection, in particular in elderly patients. The Fondazione Italiana Linfomi has recently published a multicentre prospective observational study, the 'Elderly Project', on the outcome of DLBCL in patients aged ≥65 years, evaluated using a simplified comprehensive geriatric assessment. The aim of this study was to compare biological and clinical features of HCV positive (HCV+) with HCV negative (HCV-) cases. A total of 89 HCV+ patients were identified out of 1095 evaluated for HCV serology (8.1%). The HCV+ patients were older, less fit, and had frequent extranodal involvement. The cell-of-origin determination by Nanostring showed that HCV+ cases less frequently had an activated B-cell profile compared to HCV- patients (18% vs. 43%). In all, 86% of HCV+ patients received rituximab-cyclophosphamide, doxorubicin, vincristine (Oncovin) and prednisone (R-CHOP)-like immunochemotherapy. Grade 3-4 liver toxicity occurred in 3% of cases. Among centrally reviewed cases confirmed as DLBCL, the 3-year overall survival of HCV+ patients was very similar to HCV- (63% vs. 61%, p = 0.926). In all, 20 HCV+ patients were treated with direct-acting antiviral agents (DAAs), with good tolerance and sustained virological response in all cases. The 3-year progression-free survival for this subgroup was excellent (77%), suggesting DAAs' possible role in reducing the risk of relapse by eliminating the viral trigger.
引用
- Arcari A, Tabanelli V, Merli F, et al. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi. Br J Haematol. 2023. PMID: 36733229. doi:10.1111/bjh.18678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。